Prevention and treatment of anxiety and depression in employees from across the Midlands region in the United Kingdom. Mental and Behavioural Disorders
Conditions
Interventions
Participants are randomly allocated through blocked randomised with stratification into the REST intervention or a waitlist control. We stratify across different employer sites in the Midlands to ensu
Sponsors
University of Warwick
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Able to give informed consent 2. English-speaking 3. In employment (including being on furlough) 4. Insomnia Severity Index score 5 or Patient Health Questionnaire-9 score >5 6. =18 years of age
Exclusion criteria
Exclusion criteria: 1. Currently receiving treatment (psychological or pharmacological) from mental health services (e.g. GP, private clinic, Improving Access to Psychological Therapies (IAPT) services, specialist and community mental health services) 2. Retiring in the next 10 months 3. Currently taking part in other psychological intervention trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 28/10/2021: 1. Number of organisations contacted and participating in the trial measured using recruitment and participation data collected during the recruitment process and throughout the trial 2. Number of employees registering interest, screening for, and participating in the trial measured using recruitment and participation data collected during the recruitment process and throughout the trial 3. Number of topics covered by each participant on platform measured using usage data collected by the platform over the 8 week intervention period 4. Average duration to cover each topic by each participant measured using usage data collected by the platform over the 8 week intervention period Previous primary outcome measure: 1. Anxiety is measured using the General Anxiety Disorder-7 at baseline, post-intervention (8-weeks) and follow-up (12-weeks) 2. Depression is measured using the Patient Health Questionnaire-9 at baseline, post-intervention (8-weeks) and follow-up (12-weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 28/10/2021: 1. Anxiety is measured using the General Anxiety Disorder-7 at baseline, post-intervention (8-weeks) and follow-up (12-weeks) 2. Depression is measured using the Patient Health Questionnaire-9 at baseline, post-intervention (8-weeks) and follow-up (12-weeks) 3. Job productivity measured through Work Productivity and Activity Impairment: General Health v2.0 at baseline, post-intervention (8-weeks) and follow up (12-weeks) 4. Job satisfaction measured using the Indiana Job Satisfaction Scale at baseline, post-intervention (8-weeks) and follow up (12-weeks) 5. Well-being measured using the Warwick-Edinburgh Mental Health Well-being Scale at baseline, post-intervention (8-weeks) and follow up (12-weeks) 6. Quality of life measured using the EuroQOL EQ-5D-5L questionnaire at baseline, post-intervention (8-weeks) and follow up (12-weeks) Previous secondary outcome measures: 1. Job productivity measured through Work Productivity and Activity Impairment: General Health v2.0 at baseline, post-intervention (8-weeks) and follow up (12-weeks) 2. Job satisfaction measured using the Indiana Job Satisfaction Scale at baseline, post-intervention (8-weeks) and follow up (12-weeks) 3. Well-being measured using the Warwick-Edinburgh Mental Health Well-being Scale at baseline, post-intervention (8-weeks) and follow up (12-weeks) 4. Quality of life measured using the EuroQOL EQ-5D-5L questionnaire at baseline, post-intervention (8-weeks) and follow up (12-weeks) 5. User Experience behaviour of platform usage measured using the number of “log-in”-s and “counts” of activities completed on the platform over the 8 weeks intervention period | — |
Countries
England, United Kingdom
Contacts
Public ContactCharlotte Kershaw
Outcome results
None listed